Cracking the Code for Improved Patient Outcomes in Advanced Renal Cell Carcinoma
To claim CME please visit this link: http://bit.ly/3YQqiXv
.75 CME | MOC
In this case based discussion, discover recent clinical trial findings on checkpoint inhibitors and VEGFR-directed therapies that can inform personalized care plans for patients with renal cell carcinoma (RCC). Dr. Eric Jonasch, Professor in the Department of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center, will provide expert perspectives on the myriad of novel therapeutic options for advanced RCC. Start the activity now!
STATEMENT OF NEED
Renal cell carcinoma (RCC) comprises 2.4% of malignancies in adults worldwide (Makino et al, 2022). It is estimated that 79,000 new cases of kidney cancer were diagnosed in the US in 2022 (Siegel et al, 2022). RCC is characterized by a lack of early warning signs, diverse clinical manifestations, and resistance to radiation and chemotherapy. Several new therapies have been approved for RCC in recent years; therefore, it is important for the cancer care team to update their knowledge of RCC pathophysiology and the benefits and risks of novel therapies. In this activity presented at the Society of Government Service Urologists James C. Kimbrough Urological Seminar, Eric Jonasch, MD, Professor in the Department of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center, imparts expert perspectives and details the latest treatment options for advanced RCC.
TARGET AUDIENCE
Military, academic, and private practice urologists, nurse practitioners, and physician assistants involved in the treatment of patients with renal cell carcinoma.
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:
Discuss the immunogenicity of RCC and the implications for the treatment of advanced disease
Assess criteria for risk stratification of patients with advanced RCC
Evaluate recent clinical trial findings on novel treatment strategies for advanced RCC with checkpoint inhibitors and VEGFR-directed therapies
-
Category
No comments found